The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), ...

DexCom, Inc. DXCM recently announced that its G6 continuous glucose monitoring (“CGM”) System will be available to diabetic military members, their families and retirees as a TRICARE brand-name ...

Dexcom G6 is the first Continuous Glucose Monitoring (CGM) System to be listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a leader in ...

Please provide your email address to receive an email when new articles are posted on . The FDA on Tuesday approved the use of a professional continuous glucose monitoring system from Dexcom, ...

Dexcom, Inc., a leader in continuous glucose monitoring (CGM), announced today that the company has received CE Mark for its Dexcom G6 System for people with diabetes ages two years and up. "The ...

Dexcom, a global leader in real time continuous glucose monitoring for people with diabetes, is releasing the Dexcom G6 mobile app in Spanish, available immediately for users with a compatible iOS (v1 ...

The Dexcom G6 iCGM system determines blood glucose levels in patients 2 years of age and older. The Food and Drug Administration (FDA) has authorized the marketing of the Dexcom G6 integrated ...

Dexcom G6 gives people with diabetes the power to manage their condition without fingersticks* or scanning Proven to improve glycemic control and can reduce the risk of costly long-term ...

The U.S. Food and Drug Administration today permitted marketing of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for determining blood glucose (sugar) levels in children aged ...